FY2025 reported revenue growth, calculated from annual net sales. Growth does not establish organic or constant-currency performance.2025 财年披露口径的收入增长率，由年度净销售额计算。该增长率不能等同于有机增长或固定汇率增长。
Kane Xie · Independent researchKane Xie（谢昆仑）· 独立研究
Zimmer Biomet
Medical Device Market & Competitive Intelligence医疗器械市场研究与竞争情报
An independent research case study on orthopedic devices, business performance, product strategy and commercial research opportunities.围绕骨科器械、经营表现、产品策略及商业研究方向开展的独立研究案例。
Knees / total & partial膝关节／全膝与部分置换Hips / primary & revision髋关节／初次与翻修S.E.T. / specialty orthopedicsS.E.T.／专科骨科产品Robotics & surgical technology机器人与手术技术
Source / 来源： Zimmer Biomet 2025 Annual ReportZimmer Biomet 2025 年度报告Executive summary研究摘要
This self-initiated case study examines how Zimmer Biomet’s financial performance, orthopedic portfolio and selected competitors can inform practical business research. It combines source-level financial checks with product-category mapping, while keeping commercial hypotheses separate from verified findings.本自主研究案例探索如何通过 Zimmer Biomet 的财务表现、骨科产品组合及部分竞争对手资料，为实际商业研究提供支持。研究结合原始财务资料核对与产品分类梳理，并将商业假设与已验证发现明确区分。
Research questions研究问题
- What do the company’s business and revenue categories reveal about its orthopedic focus?公司的业务与收入分类体现了怎样的骨科重点？
- How did revenue, GAAP profitability and cash generation change across three complete fiscal years?三个完整财年中，收入、GAAP 盈利与现金生成能力如何变化？
- Which product and competitor dimensions can be compared using accessible public evidence?哪些产品与竞品维度可以通过公开证据进行比较？
- What follow-up research could help a manufacturer, exporter or distributor make a more informed decision?哪些后续研究有助于制造商、出口商或经销商作出更充分的判断？
FY2025 GAAP operating margin, down from 16.7% in FY2024. Higher revenue did not translate into higher GAAP operating profit.2025 财年 GAAP 营业利润率，低于 2024 财年的 16.7%。收入增加并未带来 GAAP 营业利润增加。
FY2025 operating cash flow, above FY2024. Cash generation and accounting earnings answer different questions.2025 财年经营活动现金流，高于 2024 财年。现金生成能力与会计利润反映不同问题。
Business implications商业启示
A useful competitor brief needs more than a revenue headline. Portfolio mix, acquisition timing, GAAP cost items and local product availability all affect interpretation. This study provides a starting framework; it does not establish market share, customer demand or an investment recommendation.有价值的竞品简报不能只展示收入增长。产品组合、收购时点、GAAP 成本项目及地区产品可获得性均会影响判断。本研究提供初步框架，不构成市场份额、客户需求或投资建议的结论。
Coverage: annual financials for FY2023–2025; selected product pages and source-access checks as of 2026-10-19. Latest quarterly results and a normalized peer financial comparison are outside this completed scope.研究范围：2023—2025 财年年度数据，以及截至 2026-10-19 的部分产品页面与来源访问检查。最新季度结果及统一口径的竞品财务比较尚未纳入。
Company overview公司概况
Zimmer Biomet is an orthopedic and musculoskeletal-care company. Its FY2025 report organizes products into knees, hips, S.E.T., and technology & data, bone cement and surgical products. S.E.T. includes sports medicine, biologics, foot and ankle, upper extremities, trauma and craniomaxillofacial / thoracic products.Zimmer Biomet 是骨科及肌肉骨骼健康领域的医疗器械企业。2025 财年报告将产品分为膝关节、髋关节、S.E.T.，以及技术与数据、骨水泥和手术产品。S.E.T. 包括运动医学、生物制品、足踝、上肢、创伤，以及颅颌面与胸部相关产品。
The report describes sales in more than 100 countries and regional operations spanning the Americas, EMEA and Asia Pacific. Regional sales-channel descriptions are context for further distributor research, rather than proof that a particular product is available in every country.年报披露其产品销售覆盖超过 100 个国家，区域业务包括美洲、欧洲／中东／非洲及亚太。区域销售渠道信息可为进一步的经销商研究提供背景，但不能证明每种产品在所有国家均可销售。
Company-disclosed events: the FY2025 report records acquisitions of Paragon 28 and Monogram Technologies. These changes make acquisition timing relevant when comparing year-on-year portfolio performance.公司披露事项：2025 财年报告记录了对 Paragon 28 和 Monogram Technologies 的收购。因此，在比较年度产品组合表现时，需要考虑收购时间的影响。
Source / 来源： Zimmer Biomet 2025 Annual ReportZimmer Biomet 2025 年度报告Research interpretation: separate implant categories, enabling technology and regional access when building a market map. Company-wide sales cannot be used as a proxy for a specific implant market’s size.研究解读：市场图谱应区分植入物品类、配套技术与地区准入。不能以公司整体收入代替某个植入物细分市场的规模。
Financial analysis财务分析
All monetary values below are USD millions. Years end December 31. Net income means net earnings attributable to Zimmer Biomet Holdings, Inc. Operating profit and net income use GAAP figures from the same FY2025 consolidated comparative statements.以下金额单位均为百万美元，财年截止日为 12 月 31 日。净利润指归属于 Zimmer Biomet Holdings, Inc. 的净利润。营业利润和净利润均采用 2025 年报同一组比较合并报表中的 GAAP 数据。
Revenue trend营业收入趋势
USD millions · FY2023–2025单位：百万美元 · 2023—2025 财年
Net sales净销售额
GAAP operating marginGAAP 营业利润率
% of net sales · FY2023–2025单位：占净销售额的百分比 · 2023—2025 财年
Operating margin营业利润率
Cash generation and capital additions经营现金流与资本性支出
USD millions · FY2023–2025单位：百万美元 · 2023—2025 财年
Operating cash flow经营活动现金流Capital additions资本性支出Calculated cash remainder计算现金余量
Read earnings and cash flow together结合利润与现金流进行解读
Parent-attributable GAAP net income declined from $1,024.0m to $903.8m and $705.1m across FY2023–2025, while operating cash flow was $1,581.6m, $1,499.4m and $1,697.1m. Depreciation, amortization and working-capital movements reconcile earnings to operating cash flow in the source statement; the gap alone does not prove earnings quality or a sustainable trend.2023—2025 财年，归属母公司的 GAAP 净利润依次为 1,024.0、903.8 和 705.1 百万美元；经营活动现金流依次为 1,581.6、1,499.4 和 1,697.1 百万美元。原始现金流量表通过折旧、摊销和营运资本变动等项目调节净利润与经营现金流的差异；不能仅凭差额判断盈利质量或趋势是否可持续。
Inspect the underlying annual data and calculations查看年度原始数据与计算口径
| Metric · USD millions unless noted指标 · 除另有说明外，单位为百万美元 | FY20232023 财年 | FY20242024 财年 | FY20252025 财年 |
|---|---|---|---|
| Net sales净销售额 | 7,394.2 | 7,678.6 | 8,231.5 |
| GAAP operating profitGAAP 营业利润 | 1,277.7 | 1,285.7 | 1,098.1 |
| GAAP net income, parent-attributableGAAP 归属母公司净利润 | 1,024.0 | 903.8 | 705.1 |
| Operating cash flow经营活动现金流 | 1,581.6 | 1,499.4 | 1,697.1 |
| Additions to instruments (outflow)器械工具新增支出（流出） | 311.7 | 240.3 | 300.5 |
| Other PPE additions (outflow)其他固定资产新增支出（流出） | 291.1 | 203.8 | 224.5 |
| Capital additions (calculated)资本性支出（计算值） | 602.8 | 444.1 | 525.0 |
| Cash remainder (calculated, non-GAAP)现金余量（计算值，非 GAAP） | 978.8 | 1,055.3 | 1,172.1 |
No adjusted earnings series is mixed into GAAP figures. Company-reported non-GAAP measures require their own definitions and reconciliations. FY2023 revenue growth is omitted because FY2022 was not extracted into this dataset. Statement locators: printed p. 39 (earnings), p. 43 (cash flows).图表没有将调整后利润混入 GAAP 数据。公司披露的非 GAAP 指标需要单独核查定义及调节表。由于数据集中未提取 2022 财年，未展示 2023 财年收入增长率。原文定位：年报印刷页码第 39 页（利润表）、第 43 页（现金流量表）。
Download the structured research dataset (JSON)下载结构化研究数据（JSON）
Product portfolio analysis产品组合分析
The categories below use the FY2025 portfolio disclosure and selected official product pages. Inclusion documents public-source evidence; it does not establish current inventory, authorization or commercial availability in a particular jurisdiction. No product images or proprietary marketing diagrams have been copied.以下分类依据 2025 财年产品组合披露及部分官方产品页面。列入此处仅表示存在公开来源依据，不代表特定地区当前有库存、已获授权或具备商业供应条件。未复制官方产品图片或专有营销图示。
Persona
Need / category: Implant system for primary total knee arthroplasty.需求／类别：用于初次全膝关节置换的植入物系统。
Public evidence: Official page describes anatomic tibial options and personalized implant fit.公开证据：官方页面介绍了解剖型胫骨组件选择及个性化匹配设计。
Research relevance: Illustrates product segmentation within the company’s knee franchise; fit options are product features, not evidence of superior outcomes.研究意义：展示膝关节业务内部的产品细分；匹配选项属于产品特征，不能据此推断临床效果更优。
Source / 来源： Persona® The Personalized Knee®Persona® 个性化膝关节系统（官方产品页）Oxford Partial Knee
Need / category: A compartment-specific alternative within the knee portfolio.需求／类别：膝关节产品组合中针对特定间室的部分置换方案。
Public evidence: The cited official page describes a cemented implant for the medial compartment; this does not establish availability of every Oxford variant.公开证据：所引官方页面介绍的是骨水泥固定的内侧间室植入物，不代表所有 Oxford 型号均已验证或可获得。
Research relevance: Shows why total and partial knee offerings should be researched separately when mapping competitors.研究意义：说明建立竞品图谱时，应将全膝关节与部分膝关节产品分开研究。
Source / 来源： Oxford® Partial KneeOxford® 部分膝关节系统（官方产品页）Taperloc Hip System / G7 Acetabular System
Need / category: Femoral and acetabular product families named in the FY2025 report.需求／类别：2025 财年报告列出的股骨侧和髋臼侧产品系列。
Public evidence: The report separates primary and revision hip procedures and names several implant families. Individual specifications were not reviewed.公开证据：年报区分了初次与翻修髋关节手术，并列出多个植入物系列；本研究未逐项审核技术规格。
Research relevance: A hip portfolio comparison should distinguish femoral stems, acetabular components and revision systems.研究意义：髋关节产品比较应区分股骨柄、髋臼组件和翻修系统。
Source / 来源： Zimmer Biomet 2025 Annual ReportZimmer Biomet 2025 年度报告ROSA robotic technologiesROSA 机器人辅助手术技术
Need / category: Surgical assistance alongside implant procedures.需求／类别：配合植入物手术的辅助技术。
Public evidence: The FY2025 report describes implant-positioning assistance for total or partial knee arthroplasty and use in hip and shoulder procedures.公开证据：2025 财年报告描述了用于全膝或部分膝关节置换的植入物定位辅助，以及在髋关节和肩关节手术中的应用。
Research relevance: Adds a technology dimension to implant comparisons. No claim of interchangeable platforms, regional clearance or clinical superiority is made.研究意义：为植入物比较加入技术维度。本研究不声称各平台可以互换，也不据此判断地区许可或临床优势。
Source / 来源： Zimmer Biomet 2025 Annual ReportZimmer Biomet 2025 年度报告Comprehensive Shoulder / JuggerKnot
Need / category: Upper-extremity reconstruction and soft-tissue repair categories.需求／类别：上肢重建与软组织修复。
Public evidence: Both brands are named within the FY2025 S.E.T. portfolio; upper extremities and sports medicine are separate subcategories.公开证据：两个品牌均列于 2025 财年 S.E.T. 产品组合；上肢和运动医学属于不同子类别。
Research relevance: Prevents shoulder reconstruction and shoulder soft-tissue repair from being treated as one market.研究意义：避免将肩关节重建与肩部软组织修复混为同一个市场。
Source / 来源： Zimmer Biomet 2025 Annual ReportZimmer Biomet 2025 年度报告Natural Nail / Gorilla Ankle Fracture Plating
Need / category: Bone stabilization and foot-and-ankle reconstruction categories.需求／类别：骨固定与足踝重建相关产品。
Public evidence: Brands are named in the FY2025 report. The report also records the 2025 acquisition of Paragon 28.公开证据：相关品牌列于 2025 财年报告，报告同时记录了当年对 Paragon 28 的收购。
Research relevance: Portfolio changes and acquisition timing matter when interpreting category growth; this is not evidence of organic growth alone.研究意义：解释品类增长时需要考虑产品组合变化与收购时点，不能将增长直接视为有机增长。
Source / 来源： Zimmer Biomet 2025 Annual ReportZimmer Biomet 2025 年度报告Product descriptions are for industry research, not medical diagnosis, treatment selection or patient-specific advice. Named trademarks belong to their respective owners.产品介绍仅用于行业研究，不构成诊断、治疗选择或个体化医疗建议。相关商标归各自权利人所有。
Competitive intelligence竞争情报
This comparison uses a consistent set of questions: category focus, representative products / robotics, evidence available, and what remains unverified. Short company profiles keep the comparison readable on mobile without a very wide matrix.比较采用统一问题框架：品类重点、代表性产品／机器人技术、可获得证据及尚未核实的问题。采用简短公司档案，避免手机端难以阅读的超宽表格。
This is a coverage framework, not a ranking. Whole-company revenue, orthopedic segment revenue, currencies, fiscal calendars and geographic scope are not interchangeable. No peer revenue or market-share comparison is presented without normalization.这是研究覆盖框架，不是企业排名。公司整体收入、骨科分部收入、币种、财年及地区范围不能互换，未统一口径前不作竞品收入或市场份额比较。
Zimmer Biomet
- Market focus市场重点
- Knees, hips, S.E.T.; technology, bone cement and surgical products.膝关节、髋关节、S.E.T.，以及技术、骨水泥与手术产品。
- Products / digital产品／数字技术
- Persona; Oxford; Taperloc; G7; ROSA.
- Public evidence公开证据
- FY2025 report plus selected current product pages. Three-year financial series verified.2025 财年报告及部分当前产品页面；已核对三年财务序列。
- Comparison limits比较局限
- Geographic availability, product-level economics and specific local regulatory status were not validated.未验证地区可获得性、单品经济性或具体地区监管状态。
Stryker
- Market focus市场重点
- Named by Zimmer Biomet as a major global competitor in knees, hips and S.E.T.Zimmer Biomet 将其列为膝关节、髋关节和 S.E.T. 领域的主要全球竞争对手。
- Products / digital产品／数字技术
- Product-level comparison pending; no unsupported robotics specification included.产品层面对比待补充；未写入缺乏依据的机器人技术规格。
- Public evidence公开证据
- Competitor relationship verified in Zimmer Biomet’s FY2025 report.竞对关系可由 Zimmer Biomet 2025 财年报告核实。
- Comparison limits比较局限
- Official portfolio page is a dynamic shell in this extraction. Peer segment financials, geography and distribution require follow-up.本次提取仅得到官方动态页面壳。其分部财务、地区与分销信息仍需进一步研究。
Johnson & Johnson MedTech / DePuy Synthes
- Market focus市场重点
- Named by Zimmer Biomet as a major competitor. Brand and corporate naming follow the cited FY2025 report.Zimmer Biomet 将其列为主要竞争对手；品牌及公司名称沿用所引 2025 财年报告。
- Products / digital产品／数字技术
- Product-level and digital-surgery comparison pending.产品及数字手术技术的具体比较待补充。
- Public evidence公开证据
- Competitor relationship verified in Zimmer Biomet’s FY2025 report.竞对关系可由 Zimmer Biomet 2025 财年报告核实。
- Comparison limits比较局限
- Official company page returned HTTP 403. Current corporate scope, specific products and comparable segment metrics need verification.官方公司页面返回 HTTP 403。当前业务边界、具体产品与可比的分部指标仍需核实。
Smith+Nephew
- Market focus市场重点
- Orthopaedics; selected knee and robotic-surgery offerings identified on its official page.骨科；其官方页面可确认部分膝关节与机器人辅助手术产品。
- Products / digital产品／数字技术
- JOURNEY II; CORI Surgical System.
- Public evidence公开证据
- Company product page and Zimmer Biomet’s competitor disclosure.依据公司产品页面及 Zimmer Biomet 的竞对披露。
- Comparison limits比较局限
- No head-to-head outcomes or market-share conclusion. Revenue scope, regional availability and channel model remain unnormalized.不作直接临床效果或市场份额结论；收入边界、地区可获得性及渠道模式尚未统一。
CHUNLI Orthopedics春立医疗（CHUNLI Orthopedics）
- Market focus市场重点
- Official navigation lists joint, spine, sports medicine, trauma and surgical robot categories.官方导航列有关节、脊柱、运动医学、创伤及手术机器人类别。
- Products / digital产品／数字技术
- Category-level evidence only; detailed model and specification comparison pending.目前仅有类别层面证据，具体型号与规格比较待补充。
- Public evidence公开证据
- Official company site; A-share 688236.SH and H-share 01858.HK listing identifiers.依据公司官网；上市标识为 A 股 688236.SH、H 股 01858.HK。
- Comparison limits比较局限
- Listed company: financial reports are available in principle, but not extracted or reconciled here. No assumed product equivalence or geographic coverage.春立为上市公司，原则上可获取财报，但本案例未提取或统一其口径。不假定产品等同性或地区覆盖。
Relationship disclosure: Kane Xie’s existing résumé identifies an internship at CHUNLI. This case study uses only public sources; that relationship is not evidence of product superiority. CHUNLI is a listed company, and its financial data should be checked against official filings before any quantitative peer comparison.关系披露：Kane Xie 的现有简历注明其在春立医疗实习。本案例仅使用公开来源，该工作关系不能作为产品优势的证据。春立医疗为上市公司，定量比较前应以正式披露核对其财务数据。
Commercial research opportunities商业研究方向
These are illustrative research directions for hypothetical manufacturers, exporters, distributors or B2B teams. They are not confirmed Zimmer Biomet business needs, validated opportunities, client engagements or revenue forecasts. Confidence describes evidence sufficiency, not probability of commercial success.以下是面向假设中的制造商、出口商、经销商或 B2B 团队的研究方向，并非 Zimmer Biomet 已确认的业务需求、已验证机会、客户项目或收入预测。置信度表示现有证据充分程度，不代表商业成功概率。
Map a focused implant category聚焦植入物细分品类
- Opportunity研究机会
- How do selected total and partial knee offerings differ in a defined country?在某一具体国家，所选全膝与部分膝关节产品有何差异？
- Evidence证据
- Persona and Oxford occupy different knee subcategories; the annual report identifies global competitors.Persona 与 Oxford 属于不同膝关节子类别；年报识别了全球竞争对手。
- Potential value潜在业务价值
- Help a manufacturer or distributor organize relevant competitor products before deeper diligence.帮助制造商或经销商在深入尽调前梳理相关竞品。
- Next validation下一步验证
- Choose a country; verify current catalogues, local registrations, distributor rights and buyer requirements.选定国家，核查现行目录、当地注册、经销权及买方需求。
- Confidence证据置信度
- Medium — The category distinction is documented; local demand and commercial feasibility are untested.中等：产品类别差异有依据，但当地需求和商业可行性尚未验证。
Monitor portfolio changes持续监测产品组合变化
- Opportunity研究机会
- Which changes require a competitor-monitoring update?哪些变化值得纳入竞品监测？
- Evidence证据
- The FY2025 report records Paragon 28 and Monogram acquisitions and a wider foot-and-ankle / robotics portfolio.2025 财年报告记录了 Paragon 28 与 Monogram 的收购，以及足踝／机器人产品组合扩展。
- Potential value潜在业务价值
- Create a dated change log separating portfolio expansion from ongoing product activity.建立带日期的变化记录，区分收购带来的组合扩展和持续产品活动。
- Next validation下一步验证
- Compare transaction announcements, later filings and regional product pages; separate acquired from organic sales where disclosed.对照交易公告、后续披露及地区产品页；有披露时区分收购贡献与有机销售。
- Confidence证据置信度
- Medium — Corporate events are disclosed, but their commercial impact requires additional evidence.中等：公司事项已披露，但商业影响仍需补充证据。
Build a qualified partner-research brief建立潜在合作伙伴研究简报
- Opportunity研究机会
- Which public distributor or importer candidates merit further validation?哪些公开可查的经销商或进口商值得进一步验证？
- Evidence证据
- The report describes sales in more than 100 countries and differing regional sales channels.年报描述销售覆盖超过 100 个国家，并介绍不同地区的销售渠道。
- Potential value潜在业务价值
- Support public-source B2B account screening and English research briefs. No lead list has been produced in this case study.支持公开来源的 B2B 企业筛选与英文研究简报。本案例尚未制作潜在客户名单。
- Next validation下一步验证
- Define geography and category; check official partner evidence, business registries, local product status and contact accuracy.明确地区与品类，核查官方合作证据、企业登记、当地产品状态及联系方式准确性。
- Confidence证据置信度
- Low — A useful research direction, without validated partner candidates, customer interviews or buyer demand.较低：目前只是值得研究的方向，尚无经过验证的合作方、客户访谈或买方需求证据。
Research methodology研究方法
- Define the questions. Focus on orthopedic categories, comparable annual financials and practical follow-up research.定义问题：聚焦骨科类别、可比年度财务及实用的后续研究。
- Identify reliable sources. Start with the company annual report and official product sites; log inaccessible pages.识别可靠来源：从公司年报与官方产品网站开始，并记录无法访问的页面。
- Collect and organize. Extract the FY2025 comparative earnings and cash-flow statements, then store figures, products and sources in a separate JSON dataset.收集与整理：提取 2025 年报中的比较利润表与现金流量表，将财务、产品和来源保存在独立 JSON 数据集中。
- Check material facts. Match figures to statement labels, preserve parent-attributable net income and distinguish disclosed numbers from calculated metrics.核查关键事实：将数值与报表项目逐项对应，保留归属母公司净利润的定义，区分披露数据和计算指标。
- Compare consistently. Use the same qualitative fields for each peer and retain evidence gaps instead of filling them with estimates.一致比较：对各竞对使用同一组定性字段，保留证据缺口，不以估算填补。
- Analyze implications. Frame commercial ideas as hypotheses with evidence, confidence and next validation steps.分析商业意义：将商业方向表述为附有证据、置信度和下一步验证步骤的假设。
- Document limits. Publish sources, reporting periods, definitions and uncompleted research alongside the findings.记录局限：同步公开来源、报告期间、定义及尚未完成的研究。
AI’s role: AI assisted discovery, extraction, structuring, English drafting, chart generation and website development. AI is not a fact source and does not independently verify claims. The material facts presented here were checked against the cited source text; calculations are reproducible from the dataset. Reader review remains appropriate before commercial reuse.AI 的作用：辅助资料发现、提取、结构化、英文撰写、图表生成和网站开发。AI 本身不是事实来源，也不能独立核实结论。页面中的重要事实已对照所引原始来源文本检查，计算可由数据集复现。用于商业用途前仍应人工复核。
No customer interviews, paid-database access, fieldwork, regulatory diligence or confidential employer information were used.本研究未开展客户访谈、付费数据库检索、实地调研或监管尽职调查，也未使用雇主保密信息。
Sources & evidence来源与证据
Research cutoff and web-access date: 2026-10-19. Financial coverage ends December 31, 2025. Undated web pages are identified as such; a successful HTTP response alone is not treated as verification of their content.研究截止日与网页访问日期：2026-10-19。财务数据覆盖至 2025 年 12 月 31 日。未注明日期的网页已作相应记录；仅收到 HTTP 成功响应不等于已核实其内容。
- Zimmer Biomet 2025 Annual ReportZimmer Biomet 2025 年度报告
Zimmer Biomet Holdings, Inc. · Publication date: not recorded / page undated. Data period: FY2025; comparative FY2024 and FY2023.发布方：Zimmer Biomet Holdings, Inc.。发布日期：未独立记录。数据期间：2025 财年，并包含 2024 与 2023 财年比较数据。
Location: Printed pp. 5–6, 8, 26–29, 39 and 43定位：年报印刷页码第 5—6、8、26—29、39 和 43 页。
Supports: Business and product categories; named competitors; revenue, GAAP earnings and cash flows. Publication date not independently recorded.支持内容：业务及产品分类、主要竞对、收入、GAAP 利润及现金流。未独立记录出版日期。
Access: Verified: downloaded and relevant tables extracted访问状态：已下载并提取相关报表。
- Persona® The Personalized Knee®Persona® 个性化膝关节系统（官方产品页）
Zimmer Biomet · Publication date: not recorded / page undated. Data period: Web page accessed at research cutoff.发布方：Zimmer Biomet。发布日期：未记录／网页未注明。数据期间：研究截止日访问的网页。
Location: Features; product overview定位：产品特征与概述。
Supports: Total knee positioning and anatomic implant options. No clinical superiority claim is adopted.支持内容：全膝关节产品定位及解剖型植入物选择；不采纳临床优越性结论。
Access: Verified: official page accessed访问状态：已访问官方网页。
- Oxford® Partial KneeOxford® 部分膝关节系统（官方产品页）
Zimmer Biomet · Publication date: not recorded / page undated. Data period: Web page accessed at research cutoff.发布方：Zimmer Biomet。发布日期：未记录／网页未注明。数据期间：研究截止日访问的网页。
Location: Product overview; indications定位：产品概述与适应证说明。
Supports: Partial knee category; the cited page describes the cemented medial-compartment product.支持内容：部分膝关节产品分类；所引页面介绍骨水泥固定的内侧间室产品。
Access: Verified: official page accessed访问状态：已访问官方网页。
- Orthopedic Products & Solutions骨科产品与解决方案（Zimmer Biomet）
Zimmer Biomet · Publication date: not recorded / page undated. Data period: Web page accessed at research cutoff.发布方：Zimmer Biomet。发布日期：未记录／网页未注明。数据期间：研究截止日访问的网页。
Location: Product category navigation定位：产品分类导航。
Supports: Navigation to official product references; annual report supplies the portfolio facts.支持内容：官方产品资料入口；产品组合事实以年报为主要依据。
Access: Verified: official page accessed访问状态：已访问官方网页。
- Orthopaedics product portfolio骨科产品组合（Smith+Nephew）
Smith+Nephew · Publication date: not recorded / page undated. Data period: Web page accessed at research cutoff.发布方：Smith+Nephew。发布日期：未记录／网页未注明。数据期间：研究截止日访问的网页。
Location: Orthopaedics; featured products定位：骨科及重点产品。
Supports: CORI Surgical System and JOURNEY II product names; category-level comparison only.支持内容：CORI Surgical System 和 JOURNEY II 产品名称，仅用于类别层面的比较。
Access: Verified: official page accessed访问状态：已访问官方网页。
- Company website and product navigation公司官网与产品导航（春立医疗）
Beijing Chunlizhengda Medical Instruments Co., Ltd. · Publication date: not recorded / page undated. Data period: Web page accessed at research cutoff.发布方：北京市春立正达医疗器械股份有限公司。发布日期：未记录／网页未注明。数据期间：研究截止日访问的网页。
Location: Product centre; investor relations; listing information定位：产品中心、投资者关系及上市信息。
Supports: Joint, spine, sports medicine, trauma and surgical robot categories; A/H listing identifiers. Marketing claims of leadership are not adopted.支持内容：关节、脊柱、运动医学、创伤、手术机器人类别及 A/H 股上市标识。不采纳宣传性领先结论。
Access: Verified: official page accessed访问状态：已访问官方网页。
- Orthopaedics portfolio骨科产品组合（Stryker）
Stryker · Publication date: not recorded / page undated. Data period: Access attempted at research cutoff.发布方：Stryker。发布日期：未记录／网页未注明。数据期间：研究截止日尝试访问。
Location: Dynamic portfolio page定位：动态产品组合页面。
Supports: Page returns HTTP 200 but usable product detail was not extracted. Peer identification uses Zimmer Biomet annual report.支持内容：网页返回 HTTP 200，但未提取到可用产品细节；竞对关系采用 Zimmer Biomet 年报作为依据。
Access: Limited: page shell accessible; detailed comparison pending访问状态：仅能读取页面壳，详细比较待补充。
- DePuy Synthes company pageDePuy Synthes 公司页面
Johnson & Johnson MedTech · Publication date: not recorded / page undated. Data period: Access attempted at research cutoff.发布方：Johnson & Johnson MedTech。发布日期：未记录／网页未注明。数据期间：研究截止日尝试访问。
Location: Company page定位：公司介绍页面。
Supports: No claims based on inaccessible page. Peer identification uses Zimmer Biomet annual report.支持内容：未基于无法访问的页面提出事实结论；竞对关系采用 Zimmer Biomet 年报作为依据。
Access: Unavailable: HTTP 403 during research访问状态：研究时返回 HTTP 403，无法访问。
Limitations & disclaimer局限与免责声明
This case study is an independent research project based on publicly available information. It is not affiliated with, sponsored by, or endorsed by Zimmer Biomet or any other company discussed. The analysis is intended for educational and portfolio purposes only and does not constitute investment, medical, legal, or regulatory advice. Findings are subject to the availability, accuracy, and limitations of public sources.本案例为基于公开信息的独立研究，与 Zimmer Biomet 或文中其他公司不存在就本研究的隶属、赞助或背书关系。分析仅用于学习与作品集展示，不构成投资、医疗、法律或监管建议。研究结论受公开来源的可获得性、准确性及其他限制影响。
- FY2026 quarterly results have not been integrated. The cutoff is an access date, not a claim that every current disclosure has been reviewed.尚未纳入 2026 财年季度结果。截止日是资料访问日期，不代表已审阅当时所有可获取披露。
- Peer financials, country-level availability, distribution arrangements and market shares remain unverified or not directly comparable.竞品财务、国家层面的产品供应、分销安排及市场份额仍未核实，或不能直接比较。
- Some official competitor pages were blocked or yielded only dynamic page shells. Those gaps are explicitly retained.部分竞对官方页面访问受限，或仅返回动态页面壳；这些缺口已明确保留。
- The product map is selective. Portfolio membership reported in FY2025 does not guarantee unchanged status at the cutoff.产品图谱为选择性研究。2025 财年报告中出现的产品，不代表截至研究日其状态始终不变。
- Commercial directions require additional evidence and prospective-customer validation. No real client outcomes are claimed.商业方向需要补充证据并与潜在客户验证，不声称真实客户项目成果。
What I can help with我可以提供哪些研究支持
I am developing practical capabilities in medical device market research, competitor and product mapping, public-source B2B lead research, English research briefs, presentation materials and AI-assisted research workflows. This independent case demonstrates a defined scope, rather than a record of paid client delivery.我正在积累医疗器械市场研究、竞品与产品图谱、公开来源 B2B 客户研究、英文简报、演示资料及 AI 辅助工作流方面的实践能力。本独立案例展示特定范围的研究成果，不代表已有付费客户交付记录。
Need structured research on medical device markets, competitors or potential B2B partners? Let’s discuss your research requirements.如果你需要医疗器械市场、竞争对手或潜在 B2B 合作伙伴的结构化研究，欢迎沟通具体需求。
Discuss a research brief →沟通研究需求 →